Systemic radiopharmaceutical therapy of painful osteoblastic metastases

https://doi.org/10.1053/srao.2000.6592Get rights and content

Bone pain from osteoblastic metastases can be ameliorated 40% to 80% of the time. Although we can predict nonresponders, we cannot predict responders; however, patients with a better performance scale may have a better chance of pain relief. Radiopharmaceuticals containing phosphorus 32, strontium 89, samarium 153, rhenium 186, and tin 117m are effective, but we do not know which is the most efficacious and the safest. Toxicity includes the flare phenomenon and mild to moderate pancytopenia, but disseminated intravascular coagulation can cause severe, life-threatening thrombocytopenia. This treatment may be repeated at about 9- to 12-week intervals, perhaps earlier with 153Sm lexidronam, 186Re etidronate, and 117mSn pentetate, with a success rate approaching that of the initial injection. The duration of action of pain reduction ranges from 2 weeks to many months. Tumorical effects are probably not the only mechanism of pain relief.

References (48)

  • DeutschE et al.

    The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine

    Nucl Med Biol

    (1986)
  • GarrettIR

    Bone destruction in cancer

    Semin Oncol 20

    (1993)
  • World Health Organization: Cancer pain relief and palliative care. Report of a WHO expert committee. World Health Organization Technical Report Series 804

    World Health Organization, Geneva, Switzerland

    (1990)
  • AtkinsHL

    Radiopharmaceuticals for bone malignancy

    J Nucl Med Technol

    (1998)
  • McEwanAJ

    Palliation therapy with bone seeking radiopharmaceuticals

    Cancer Biother Radiopharm

    (1998)
  • HosainF et al.

    Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background

    Semin Nucl Med

    (1992)
  • Ben-JosefE et al.

    Selective accumulation of strontium-89 in metastatic deposits in bone; Radiohistological correlation

    Nucl Med Commun

    (1995)
  • BlakeGM et al.

    Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate

    Eur J Nucl Med

    (1986)
  • LoganKW et al.

    Radiation dose calculations in persons receiving injections of samarium-153 EDTMP

    J Nucl Med

    (1987)
  • KrishnamurthyGT et al.

    Tin-117m(4+) DTPA: Pharmacokinetics and imaging characteristics in patients with metastatic bone pain

    J Nucl Med

    (1997)
  • EaryJF et al.

    Samarium-153-EDTMP biodistribution and dosimetry estimation

    J Nucl Med

    (1993)
  • SamartungaRC et al.

    A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP

    J Nucl Med

    (1995)
  • deKlerkJMH et al.

    Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

    Eur J Nucl Med

    (1994)
  • QuirijenJMSP et al.

    Efficacy of rhenium-186 etidronate in prostate cancer patients with metastatic bone pain

    J Nucl Med

    (1996)
  • Cited by (0)

    View full text